6th August 2018
New published study demonstrating LipiSperse®'s superior bioavailability of curcumin.
A new study published in the European Journal of Nutrition shows that LipiSperse®, a novel dispersion technology system, increases the bioavailability of curcumin.
Curcumin has been shown to deliver positive effects against numerous conditions associated with high levels of inflammation and oxidative stress. However, Curcumin is also known for its poor bioavailability and its difficulty in delivering a high concentration therapeutic dose.
LipiSperse®, developed by Pharmako Biotechnologies (Australia) is a food grade, cold water dispersible (CWD) technology that enhances the bioavailability of hydrophobic agents such as curcumin in aqueous environments. The net effect translates to an overall higher active and absorbable load with low excipients, allowing for better functionality of the ingredient.
In the study conducted at the University of Queensland, applicants volunteered to patriciate in the single equivalent dose, randomized, double-blinded study and a seven volunteers further participated in the crossover phase of the trial. In both the parallel and crossover trial, Curcumin with LipiSperse® (HydroCurc®) delivered significantly higher plasma curcuminoid concentrations (807 ng/mL) compared to the raw curcumin product (318 ng/mL). Concluding that LipiSperse® demonstrates superior bioavailability for the supply of curcumin when compared to a standard curcumin extract.
LipiSperse provides a broad range of applications for manufacturers, and it can be formulated in powders, tablets, capsules, dietary supplements, and functional foods and beverages. Pharmako Biotechnologies are represented in the USA by Gencor Pacific (California). Both LipiSperse® and HydroCurc® were finalists in the prestigious NutraIngredient Awards earlier this year in Geneva.
New LipiSperse® study featured in the European Journal of Nutrition 2018.